Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
Recruiting · Phase 1 · NCT05526924
Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma, Head and Neck Cancer Stage IV, Head and Neck Cancers - Throat
At a glance
- Research payments reported, 2025
- $117,303
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 30
About the trial
- Sponsor
- University of Chicago
- Tested
- Chemoradiation (radiation), Pamiparib (drug), Hydroxyurea (drug), Fluorouracil (5FU) (drug), Tislelizumab (drug)
- Dates
- Started 2023-03-07; completion 2028-01-01
- Results posted
- Not yet
The purpose of this study is to evaluate the safety, tolerability and maximum tolerated dose of tislelizumab in combination with pamiparib plus chemoradiotherapy (chemotherapy and radiation) in individuals with recurrent head and neck cancer, which means that the person's cancer has come back after treatment. Participation in the study should last for about 15 months while participants receive tislelizumab and chemoradiotherapy with pamiparib. Afterwards, they will return to the clinic for follow up every 4 months for 2 years, every 6 month for the next 2 years, and then once a year for the rest of their life.
From ClinicalTrials.gov, last updated 2026-03-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beigene Switzerland GmbH reported $117,303 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- The University of Chicago $117,303
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.